Archived: 15th Winter Conference
on Medicinal & Bioorganic Chemistry

Opening Remarks

A Chemical Synthesis of Ritterazine B, A Marine Natural Product with Potent Anticancer Activity

Next-generation Synthesis of Antibiotics

Enzymatic Routes to the Next Generation Therapeutics

Commercial Synthesis of APIs enabled by Enzymatic Reductive Amination

Catalytic Approaches for Simplifying Complex Alkaloid Total Synthesis

Application of a Proteome-Wide Covalent Fragment Screening Platform: The Discovery of Potent, Selective, Allosteric JAK1 Inhibitors

Co-opting the Ubiquitin System for Therapeutic Benefit

Identification of a PCSK9-LDLR Disruptor Peptide with In Vivo Function

Cyclic peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure Based-Design

Development of a Nanoscale Chemistry Direct-to-Biology (D2B) Platform for High-Throughput PROTAC Synthesis

Drugging the Undruggable with Molecular Glue

Structures of Active-State Orexin Type-2 Receptor Enable Structure-Based Drug Discovery

Impacting Drug Design using NMR Solution Conformations

Structure and Property Guided Design of Cell Permeable Peptidic Degraders

Structure-Function Relationship of a CD4-binding Adnectin with Anti-HIV-1 Activity

A Synthesis-Driven Approach to Drug Discovery: CFTR Modulators

Direct-to-Biology Platform for High-Throughput Synthesis and Evaluation of Hetero-bifunctional Degraders

Optimization of  Triazolopyridazines towards a Novel Drug to Treat Cryptosporidiosis Reveals Striking Impact by Positioning of Fluorine

Discovery of a Potent and Selective BRD9 Degrader with Activity in a Preclinical Model of Synovial Sarcoma

Building a Culture of Medicinal Chemistry Knowledge Sharing

Synthesis and Functionalization of Cyclopropanes and Cyclobutanes

Innovation in the Synthesis of Complex Pharmaceuticals

Selective Functionalization of Pyridines, Diazines and Pharmaceuticals via Unconventional Intermediates

Tackling Synthetic Challenges and Applying Synthetic Technologies across the Novartis Drug Discovery Portfolio

Computational Predictions of Reactivity & Site-Selectivity with Quantum Machine Learning 

Covalent Chemical Probes – Cysteine Labeling and Beyond

Tracking Drug Action at the Cell Surface and in the Secreted Proteome

RAPID – a High-Throughput, Cell-Based Ligand Discovery Platform for Difficult to Drug Targets

Understanding Immune Cell Interactions via Photocatalysis

Function-first Proteomic Strategies for Chemical Probe Discovery in Human Cells

Discovery of the Selective CSF1R Inhibitor ARRY-382

Identification and Optimization of First-in-Class Small Molecule Inhibitors for a Novel Oncology Target

Next Generation Oxazolidinone Antibiotics for the Treatment of Tuberculosis

Discovery and Early Clinical Development of the First-in-class TPL2 Kinase Inhibitor Tilpisertib (GS-4875) for Inflammatory Diseases

Small Molecules with Big Ambitions: Approaches to Intractable Targets